MDWD vs. SANA, TYRA, SEPN, REPL, CRON, AVDL, IMTX, PLRX, BCAX, and PRTA
Should you be buying MediWound stock or one of its competitors? The main competitors of MediWound include Sana Biotechnology (SANA), Tyra Biosciences (TYRA), Septerna (SEPN), Replimune Group (REPL), Cronos Group (CRON), Avadel Pharmaceuticals (AVDL), Immatics (IMTX), Pliant Therapeutics (PLRX), Bicara Therapeutics (BCAX), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry.
MediWound vs.
Sana Biotechnology (NASDAQ:SANA) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, community ranking, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.
MediWound received 375 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 62.20% of users gave MediWound an outperform vote while only 60.61% of users gave Sana Biotechnology an outperform vote.
Sana Biotechnology has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.
Sana Biotechnology presently has a consensus target price of $14.25, suggesting a potential upside of 350.95%. MediWound has a consensus target price of $27.50, suggesting a potential upside of 55.90%. Given Sana Biotechnology's higher probable upside, analysts plainly believe Sana Biotechnology is more favorable than MediWound.
In the previous week, Sana Biotechnology had 7 more articles in the media than MediWound. MarketBeat recorded 9 mentions for Sana Biotechnology and 2 mentions for MediWound. Sana Biotechnology's average media sentiment score of 0.42 beat MediWound's score of 0.38 indicating that Sana Biotechnology is being referred to more favorably in the media.
MediWound has higher revenue and earnings than Sana Biotechnology. MediWound is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.
88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 31.1% of Sana Biotechnology shares are owned by company insiders. Comparatively, 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Sana Biotechnology has a net margin of 0.00% compared to MediWound's net margin of -142.29%. MediWound's return on equity of -82.17% beat Sana Biotechnology's return on equity.
Summary
Sana Biotechnology beats MediWound on 9 of the 16 factors compared between the two stocks.
Get MediWound News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediWound Competitors List
Related Companies and Tools
This page (NASDAQ:MDWD) was last updated on 1/18/2025 by MarketBeat.com Staff
